Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.
Rectally administered suspensions of 5-aminosalicylic acid (5-ASA) are topically effective in treating left-sided ulcerative colitis. The extent to which the contents of these enemas are distributed to inflamed mucosal linings has not previously been determined. This study was undertaken to validate a technique for labeling 5-ASA with 99mTc and to quantitate the distribution of [99mTc]5-ASA in eight patients with left-sided ulcerative colitis. Eight patients underwent three colonic scintigraphic exams within five days, receiving a 60-ml radiolabeled 5-ASA enema into the unprepared rectum for each study, with sequential anterior abdominal images obtained for 4 hr. Activity within the rectum, sigmoid, descending, transverse, and ascending colon was quantitated. Over 50% of the labeled enema had advanced beyond the rectum in five of eight patients and in six of eight patients by 30 min and 60 min, respectively. The distribution of [99mTc]5-ASA was quantitatively reproducible when repeated in the same patient on different days, despite apparent visual differences. By 2 hr, the amount of the enema present within the rectum decreased significantly (P less than 0.05) compared to the initial distribution. The amount of enema present within the descending colon was increased significantly at 0.5 hr (P less than 0.05) and at 2 hr (P less than 0.01). There were no significant changes in the distribution from initial values for the sigmoid, transverse, or ascending colon at any time. In each of these cases the spread of the enema to or beyond the extent of disease was documented. In patients with left-sided ulcerative colitis, small volume [99mTc]5-ASA enemas reliably reach the area of inflammation.
Vitti
R A
RA
Department of Diagnostic Imaging, Temple University Hospital, Philadelphia, Pennsylvania.
Meyers
F
F
Knight
L C
LC
Siegel
J A
JA
Malmud
L S
LS
Fisher
R S
RS
D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D003093:Colitis, Ulcerative / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D004733:Enema; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D011817:Rabbits; D011877:Radionuclide Imaging; D013667:Technetium; D014018:Tissue Distribution
D000636:Aminosalicylic Acids; D019804:Mesalamine; D013667:Technetium